Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Edwards Lifesciences EW in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 7 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 1 | 3 | 0 | 0 |
| 2M Ago | 0 | 3 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $74.33, a high estimate of $90.00, and a low estimate of $66.00. This current average has decreased by 11.23% from the previous average price target of $83.73.
Diving into Analyst Ratings: An In-Depth Exploration
In examining recent analyst actions, we gain insights into how financial experts perceive Edwards Lifesciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Rescott | Baird | Lowers | Neutral | $68.00 | $73.00 |
| Patrick Wood | Morgan Stanley | Announces | Equal-Weight | $70.00 | - |
| Shagun Singh | RBC Capital | Lowers | Outperform | $75.00 | $85.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $66.00 | $77.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $70.00 | $76.00 |
| Joanne Wuensch | Citigroup | Lowers | Buy | $77.00 | $83.00 |
| Matthew Taylor | Jefferies | Lowers | Hold | $70.00 | $85.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $71.00 | $82.00 |
| Suraj Kalia | Oppenheimer | Maintains | Outperform | $90.00 | $90.00 |
| Danielle Antalffy | UBS | Lowers | Neutral | $75.00 | $90.00 |
| Matt Miksic | Barclays | Lowers | Overweight | $80.00 | $90.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $80.00 | $90.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Edwards Lifesciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Edwards Lifesciences: Financial Performance Dissected
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Edwards Lifesciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.98%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's net margin is impressive, surpassing industry averages. With a net margin of 26.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Edwards Lifesciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Edwards Lifesciences's ROA excels beyond industry benchmarks, reaching 3.69%. This signifies efficient management of assets and strong financial health.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
